๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)

โœ Scribed by Tetsuya Hamaguchi; Kuniaki Shirao; Atsushi Ohtsu; Ichinosuke Hyodo; Yasuaki Arai; Hiroya Takiuchi; Hirofumi Fujii; Motoki Yoshida; Hiroshi Saito; Tadamichi Denda; Wasaburo Koizumi; Hiroaki Iwase; Narikazu Boku; Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group

Publisher
Springer
Year
2011
Tongue
English
Weight
341 KB
Volume
14
Category
Article
ISSN
1436-3291

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The combination of cisplatin, doxorubici
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research
โœ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 482 KB ๐Ÿ‘ 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat